Amgen
AMGN
#59

¥3,073.52

0.03%

已结束: Nov 06, 21:00:00 PM UTC+00:00

¥3,071.01

0.08%

盘后: Nov 07, 00:59:16 AM UTC+00:00

Amgen Info

市值: ¥1.66T
0.03%
日交易量: ¥4.42B
市盈率: 26.52
股息率: 2.15%
EPS: ¥115.88
52周范围: ¥2.08K¥3.23K

网站

www.amgen.com

币种

股票

员工

28000

创立日期

Apr 8, 1980

主要交易平台

Nasdaq

行业

Biological Products, (No Diagnostic Substances)

CIK 编号

0000318154

代币化股票数据

平均代币化价格: ¥3.11K
价差: +¥45.05(+1.47%)
代币化市值: ¥53.46K
0.07%
代币化交易量（24 小时）: ¥1.64M
4.78%

发行人

Coinbase

合约列表

浏览器

etherscan.io

AMGN对美元转换器

AMGN

CNY

价格表现

低
¥2.97K

高
¥3.09K

加载数据中

请稍候，我们正在加载图表数据

Amgen社区

关于Amgen

What is Amgen?

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.